Cargando…
Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes
Over recent years, there have been several initiatives to gain access to compounds which have been deprioritized by pharmaceutical companies, but which have a data package allowing them to be used in human experimental medicine studies. Such compounds provide an invaluable resource for probing human...
Autores principales: | Hayes, Ann G., Nutt, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664819/ https://www.ncbi.nlm.nih.gov/pubmed/31384472 http://dx.doi.org/10.1002/prp2.510 |
Ejemplares similares
-
Regulating pharmaceutical companies’ financial largesse
por: Avraham, Ronen, et al.
Publicado: (2018) -
Pharmaceutical companies as the funding sources for continuing medical education
por: Kanchan, Tanuj
Publicado: (2015) -
The influence of pharmaceutical companies
por: Migone, Paolo
Publicado: (2017) -
Making pharmaceutical companies report what matters about innovation
por: Cohen, Adam, et al.
Publicado: (2021) -
The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
por: Arpinelli, Fabio, et al.
Publicado: (2006)